Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma

BACKGROUND: This phase II study was designed to evaluate the activity and safety of a combination of epirubicin, oxaliplatin and docetaxel in metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. METHODS: Forty patients with measurable distant metastases received epirubicin 50 mg/m(2...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Lauro, Luigi, Giacinti, Laura, Arena, Maria Grazia, Sergi, Domenico, Fattoruso, Silvia Ileana, Giannarelli, Diana, Lopez, Massimo
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2657908/
https://www.ncbi.nlm.nih.gov/pubmed/19267943
http://dx.doi.org/10.1186/1756-9966-28-34

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2657908/
https://www.ncbi.nlm.nih.gov/pubmed/19267943
http://dx.doi.org/10.1186/1756-9966-28-34

Ejemplares similares